{"analyses":[{"ciLowerLimit":"0.49","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.76","estimateComment":"Hazard ratio (HR) \\< 1 favours the cabazitaxel group and \\> 1 favours the mitoxantrone group.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Cox Proportional Hazard","paramValue":"0.61","statisticalComment":"Log-rank comparisons stratified according to disease measurability and ECOG performance status.","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.7","upperLimit":"6.5","value":"5.4"},{"groupId":"OG001","lowerLimit":"7.4","upperLimit":"9.6","value":"8.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"377"},{"groupId":"OG001","value":"378"}],"units":"Participants"}],"description":"Time to tumor progression is defined as the number of months from randomization until evidence of progressive disease (RECIST)","dispersionType":"95% Confidence Interval","groups":[{"description":"mitoxantrone 12 mg/m\\^2 (Day 1) by intravenous (IV) every 3 weeks, and prednisone 10 mg orally given daily","id":"OG000","title":"Mitoxantrone + Prednisone"},{"description":"cabazitaxel 25 mg/m\\^2 (Day 1) by intravenous (IV) every 3 weeks, and prednisone 10 mg orally given daily","id":"OG001","title":"Cabazitaxel + Prednisone"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed on the intention To Treat (ITT) population. The ITT population is composed of all randomized patients (i.e. patients assigned to a treatment group by the randomization, regardless of whether patients received any study drug or received a different study drug from which they were randomized).","reportingStatus":"POSTED","timeFrame":"From the date of randomization up to 104 weeks (study cut-off)","title":"Time to Tumor Progression","type":"SECONDARY","unitOfMeasure":"Months"}